+351 910 091 731

Code of Conduct
By-laws of the CLS
Privacy Notice 

CLS is happy to welcome new member Sobi to our community - improving lives for people with rare diseases.

4 January 2022

Sobi is an international biopharmaceutical company focused on rare diseases, founded in Sweden in 1931. With the head office in Stockholm is nowadays present in more than 30 countries around the world, delivering treatments to patients in over 70 countries.

Worldwide is estimated the existence of 6,000 distinct rare diseases, most untreated today - being a rare disease considered when it affects <1 in 2.000 people of the general population[1] -, and 300 million people are affected by rare diseases.  So Sobi, while dedicated to rare diseases, has as mission provide access to innovative treatments that transform life for people with rare diseases by working with stakeholders from different areas, like scientists, decision and regulatory makers and patients associations.

With more than 10 R&D programmes Sobi is specialized in several therapeutic areas such Haematology, Immunology, Paramiloidosis and a portfolio in Specialty Care. Within Haematology have become a leading company in haemophilia, where seeks to shape new standards and optimise treatment, build evidence and create sustainable access and provide community support in haemophilia care.

In Immunology portfolio, with three strongly growing products that each meet high unmet medical needs, represents a new focus that builds on Sobi heritage in rare disease.

In Portugal as well around the world Sobi is committed to improve lives for  people with rare diseases.

Welcome to contact Sobi in Portugal - António Araújo, country leader, to share ideas.

Sobi Lisbon Office
Rua Latino Coelho 87
1050-134 Lisboa, Portugal

E: W:

[1]Nguengang Wakap, S., Lambert, D.M., Olry, A. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 28, 165–173 (2020).



SOBI Portugal - improving lives for people with rare diseases
Previous Next